Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Capitol Hill Rheumatology Advocacy Goes Virtual

Carina Stanton  |  May 11, 2020

ACR volunteer leaders and staff will convene more than 100 meetings via teleconference with Congressional leaders on May 22, addressing rheumatology provider solvency and patient access to care amidst the COVID-19 pandemic.

Baricitinib Studied as Possible COVID-19 Treatment; Plus Ranitidine Removed from U.S. Market

Michele B. Kaufman, PharmD, BCGP  |  May 11, 2020

Baricitinib, an oral JAK1/JAK2 inhibitor approved to treat RA in adults, is being investigated as a possible treatment for hospitalized patients with COVID-19…

Serum Interleukin 6 Levels May Predict Presentation of IgG4-Related Disease

Lara C. Pullen, PhD  |  May 11, 2020

A retrospective study found serum interleukin 6 levels at the onset of IgG4-RD may significantly correlate with clinical inflammatory parameters and the involvement of the bile duct, liver and spleen…

The COVID-19 Global Rheumatology Alliance: Its Genesis, Development & Goals

Philip C. Robinson, MBChB, PhD, FRACP  |  May 8, 2020

Editor’s note: We are sad to announce that we have learned of the passing of Dr. Philip C. Robinson. We will share more as it becomes available, but in the meantime, we wanted to repost this article he wrote for The Rheumatologist early in the pandemic. Dr. Robinson also took the photo of the full-arc rainbow  below.

UnitedHealthCare Rescinds Planned Changes to Orencia Policy

From the College  |  May 6, 2020

UnitedHealthcare (UHC) is rescinding changes to its Orencia policy previously scheduled to go into effect July 1, 2020. These changes would have required patients to fail to respond to the self-administered formulation of the drug prior to obtaining authorization for the physician-administered product. Some patients on Orencia received notices from UHC in late April stating…

Uneven Access & Privacy Issues Hamper Electronic Patient Healthcare Information Sharing

Linda Carroll  |  May 5, 2020

(Reuters Health)—Patient portals at U.S. hospitals leave a lot to be desired in terms of privacy when individuals want to share access with an informal caregiver, a new study finds. At nearly half of 102 hospitals included in the study, personnel advised that patients share their account password to give access to a family member…

HCQ Prolongs QT Interval in Patients with COVID-19

Will Boggs, MD  |  May 5, 2020

NEW YORK (Reuters Health)—Potentially dangerous prolongation of the QT interval is common among patients hospitalized with COVID-19 who receive hydroxychloroquine (HCQ) with or without concomitant azithromycin, according to two new studies. “This is a well-known problem with HCQ and azithromycin, which became amplified in this higher risk population,” Christina F. Yen, MD, from Beth Israel…

COVID-19 Reality Check: Collected Stories from Rheumatologists & Rheumatology Professionals

The Rheumatologist  |  May 5, 2020

A collection of compelling interviews conducted with rheumatologists and rheumatology professionals focusing on their experiences thus far in the COVID-19 pandemic.

Pharmacy Team Combats COVID-19 in NYC: Q&A with Mark J. Sinnett, PharmD, FASHP

Mary Choy, PharmD, BCGP, FASHP  |  May 1, 2020

The outbreak of the SARS-CoV-2 virus is disrupting patient care all over the world. In the U.S., many providers have had to adapt to new social distancing measures to care for patients, but struggles remain. Mark J. Sinnett, PharmD, FASHP, director of clinical and educational pharmacy services and director of the Center for Pharmacotherapy Research…

Collaborating at the Leadership Level: Q&A with Lisa Fitzgerald, MD, & George Tsokos, MD

Carina Stanton  |  May 1, 2020

Rheumatology leaders are adapting to telemedicine and other modified collaborations to adjust patient care and research during the COVID-19 pandemic…

  • « Previous Page
  • 1
  • …
  • 202
  • 203
  • 204
  • 205
  • 206
  • …
  • 815
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences